Active
Consult done
UCSF trial next
Where things stand
Stage 0 DCIS (right breast) — intermediate grade, comedonecrosis, strongly hormone-positive
(ER ~90%, PR ~60%). Not invasive on core biopsy. Accession DPS-26-17107.
Outlook for treated DCIS is excellent in population data (NCI: very high 5-year survival).
- Surgical consult complete (2026-07-22) with Dr Lisa M. Guirguis (Sutter breast surgical oncology).
- Primary next step: apply / screen for a UCSF clinical trial (non-operative / monitoring research). Trial exit anytime → surgery remains open.
- Off-trial pure watch is not recommended on the home Sutter path; non-op care only via reputable trial (UCSF / MDACC preferred).
- Care data: homework worksheet (pedigree + HRT) plus optional My Health Online / Epic pull — same Stage 0 packet, not a separate app.
- Backup path: lumpectomy with Guirguis (~1.5–2 cm field) if trial ineligible or preference changes.
Surgeon
Guirguis
Sutter · 916-733-9660
Next step
UCSF trial
Application / screening
Alt path
Lumpectomy
Open anytime
5-yr survival
>98%
NCI DCIS data
Pathology
Navigator
Surgical consult
UCSF trial apply
Intervention
Local control / monitor
HRT plan
Flourishing
Core research findings
Synthesized from 10 molecular research lanes, Sutter education canon, and pathology map. Reframe: cancer is a dysregulated cellular program — elimination means reverse or block the active program with minimum necessary intervention.
1. Hormone fuel is the primary growth driver
ER 90% / PR 60% strong positive means these cells can respond to estrogen/progesterone signaling. Endocrine therapy (tamoxifen vs AI depends on menopausal status — confirm with team) is a standard lever after local control (NSABP B-24 context for ER+ DCIS).
Clinical note: menopausal status not fully settled (perimenopause / cusp language at consult) — agent choice is a care-team decision.
2. Active HRT is systemic fuel — discuss cessation now
Dawn is on estrogen + progesterone + testosterone (per mammogram record). This directly feeds ER+/PR+ DCIS. Do not stop without oncology/PCP guidance, but cessation timing is an urgent consult question.
Mechanism: L6-systemic — exogenous hormones amplify ER-driven proliferation
3. Comedonecrosis elevates risk — active monitoring not appropriate
Intermediate grade + comedonecrosis excludes COMET-style watch-and-wait. Definitive local therapy (lumpectomy) is warranted. Comedonecrosis correlates with hypoxic cores, potential microinvasion (~15–20% upgrade risk at surgery).
Mechanism: L5-microenvironment — necrotic core, immune-cold TME, angiogenesis
4. Standard efficient path: surgery → radiation discussion → endocrine therapy
Lumpectomy with clear margins (≥2 mm) is first-line. DCISionRT genomic score on excised tissue guides radiation (score >3 → meaningful benefit). Five-year endocrine therapy if HR+. Elimination probability >95% with optimal therapy; 10-year recurrence ~5–10%.
Mechanism: L7-intervention — local removal + fuel block + surveillance
5. Dense breasts — MRI extent mapping may be discussed
Heterogeneously dense tissue masks masses. Pre-op breast MRI is a reasonable consult question to ensure complete excision.
Mechanism: L5-microenvironment — breast density, calcification cluster at R UOQ
6. Body systems are treatment-ready
Kidneys, liver, electrolytes, A1c (4.4%), lipids all favorable. Mild normocytic anemia (Hgb 11.6, ferritin 42) — not iron-deficient. Vitamin D supplementation recommended. MMR vaccine needed (measles IgG negative).
Mechanism: L6-systemic — host readiness for surgery and endocrine therapy
7. Lifestyle levers are adjunctive, not substitutes
Exercise, vitamin D (already low), weight management, and limiting alcohol complement pharmacotherapy but cannot replace endocrine blockade for ER90%+ DCIS. Pretreatment shoulder exercises should start now (9-min Sutter video).
Mechanism: L4-metabolome / L6-systemic — insulin/IGF-1, adipose aromatase, immune priming
8. Optional precision tools if equivocal
BRCA panel (no family hx but still reasonable), DCISionRT after excision, Oncotype DCIS or RNA panel if ordered, tumor-normal WGS only if pathology remains equivocal post-surgery.
Mechanism: L0-genome / L2-transcriptome — clonal drivers invisible to IHC alone
Estrogen Matters — integrated analysis
Bluming & Tavris, Estrogen Matters (2018, afterword 2021)
Ingested from ~/Downloads/774280908-Estrogen-Matters.txt · stored at .praxis/dawn-gradient/sources/estrogen-matters-bluming-tavris.txt
What the book argues: The belief that estrogen "causes" breast cancer is oversimplified and often wrong. The WHI study (2002) exaggerated HRT risks through flawed methodology. Over 90% of women diagnosed with early breast cancer are cured. ER+ status often indicates slower-growing disease with better prognosis — the receptor marks cells that adopted a normal characteristic, not proof that estrogen created the cancer.
What applies to Dawn right now:
- During active DCIS: Guirguis framed systemic HRT as residual risk (not fear-mongering): coordinate with the team; local/vaginal estrogen OK in her view; T pellet converts toward estrogen. Do not start/stop HRT alone.
- After treatment: Chapter 6 reviews observational data on breast cancer survivors taking HRT. Bluming's 14-year pilot study (248 women) found no increased recurrence. Multiple cohort studies (LA, Dallas, Seattle, Milwaukee meta-analysis) found similar or better outcomes for HRT users. The HABITS trial (often cited against HRT) had methodological flaws; the parallel Stockholm trial found no increased risk.
- Post-treatment QoL: If menopausal symptoms are severe after endocrine therapy, Estrogen Matters supports revisiting HRT with an informed oncologist — not as a blanket prohibition. Dawn's future HRT decision is a separate chapter from today's fuel-stop decision.
- Fear reduction: The book's central message supports Dawn's framing — this is a chapter, not the whole book. Early DCIS cure rates exceed 98%. Lumpectomy is appropriate; bilateral mastectomy is not indicated for localized DCIS.
Source: Avrum Bluming MD & Carol Tavris PhD, Estrogen Matters: Why Taking Hormones in Menopause Can Improve Women's Well-Being and Lengthen Their Lives — Without Raising the Risk of Breast Cancer. Little, Brown Spark, 2018.